Top Markets
Coin of the day
Entropy Neurodynamics Limited Entropy Neurodynamics Limited

Entropy Neurodynamics Limited

ENP
株式のランク #26475
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical... Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
株価
$0.02468497
最終同期: 2026-07-30
時価総額
$40.28M
変化(1日)
0.00%
変化(1年)
-
AU
取引 Entropy Neurodynamics Limited (ENP)

カテゴリー

Entropy Neurodynamics Limited(ENP)の株価履歴
終値の最高値: $0.02 (2026-07-01)

終値の最安値: $0.02 (2025-11-01)
Entropy Neurodynamics Limited の株価履歴(2025 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 14.81%
2025 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$546.54 38.59%
US
$1.04K 56.71%
NL
$120.74 -14.98%
AU
$138.98 416.85%
US
$761.87 7.04%
CH